line	nat	A

nal Application No

PCT/GB 98/02550

A. (CLA	ASSIF	ICAT	ION	OF	SUB.	JECT	MA'	TTER
ΤP	Γ	6	Γ	20	1 /	6.0			

IPC 6 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED


Minimum documentation searched (classification system followed by classification symbols) IPC-6-C120

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUM	C. DOCUMENTS CONSIDERED TO BE RELEVANT			
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
X	"stratagene catalogue" January 1997 , STRATAGENE XP002085450 see page 274 - page 277	1		
Y	EP 0 726 310 A (GEN PROBE INC) 14 August 1996 see whole doc, esp. claims 13-27	1-6		
Y	SUGANUMA A. & CUPTA K.C.: "An evaluation of primer length on random-primed DNA synthesis for nucleic acid hybridization: longer is not better" ANALYTICAL BIOCHEMISTRY, vol. 224, - 1995 pages 605-608, XP002085448 cited in the application see the whole document	1-6		

X Further documents are listed in the continuation of box C.	Patent family members are listed in annex.
"A" document defining the general state of the lart which is not considered to be of particular relevance. "E" earlier document but published on or after the international filling date. "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified). "O" document referring to an oral disclosure, use, exhibition or other means. "P" document published prior to the international filling date but later than the priority date claimed.	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention. "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone. "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family
Date of the actual completion of the international search	Date of mailing of the international search report
24 November 1998	08/12/1998
Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentiaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl. Fax: (+31-70) 340-3016	Müller, F




onal Application No PCT/GB 98/02550

		PCT/GB 98/02550	
C.(Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication where appropriate of the relevant passages	Relevant to claim No	
X	DE 195 03 685 A (INVITEK GMBH) 1 August 1996 see whole doc, esp. claims 1, 10,13; page 2,lin15 ff.	1-5	
A	DAY I.N.M. ET AL.,: "Dried template DNA, Dride PCR oligonucleotides and mailing in 96-well:LDL receptor gene mutation screening" BIOTECHNIQUES, vol. 18, no. 6, - 1995 pages 981-984, XP002085449 see esp. page 982, 3.column ff.	1-6	
Α	WO 96 30544 A (WAKEFIELD ANDREW JEREMY) 3 October 1996 see whole doc. esp. claim 14	1-6	
A	US 5 407 799 A (STUDIER F WILLIAM) 18 April 1995 see esp. claims (9,10)	1-6	

Information on patent family members

onal Application No PCT/GB 98/02550

Patent document cited in search repor	t	Publication date	Patent family member(s)	Publication date
EP 0726310	А	14-08-1900	US 5556771 A AU 4916796 A CA 2210584 A JP 10503383 T WO 9624664 A US 5614387 A US 5834254 A	17-09-1996 27-08-1996 15-08-1996 31-03-1998 15-08-1996 25-03-1997 10-11-1998
DE 19503685	Α	01-08-1996	NONE	
WO 9630544	Α	03-10-1900	AU 5153196 A CA 2216807 A EP 0817864 A GB 2300259 A	16-10-1996 03-10-1996 14-01-1998 30-10-1996
US 5407799	Α	18-04-1995	NONE	



TENT COOPERATION TRE, Y

	From the INTERNATIONAL BUREAU		
PCT	*v		
NOTIFICATION OF THE RECORDING OF A CHANGE (PCT Rule 92bis 1 and Administrative Instructions, Section 422)	PENNANT, Pyers Stevens Hewlett & Perkins 1 Serjeants Inn Fleet Street London EC4Y 1NT ROYAUME-UNI		
O1 June 1999 (01.06.99)			
Applicant's or agent's file reference PP 1180	IMPORTANT NOTIFICATION		
International application No. PCT GB98 02550	International filing date (day month year) 21 August 1998 (21.08.98)		
The following indications appeared on record concerning: the applicant the inventor	X the agent the common representative		
Name and Address PENNANT, Pyers Stevens Hewlett & Perlins 1 Serjeants' Inn Fleet Street London EC4Y 1LL United Kingdom	State of Nationality State of Residence Telephone No. 44-171-936-2499 Facsimile No. 44-171-936-2498 Teleprinter No.		
2. The International Bureau neleby notifies the applicant that to the person the name X the add			
Name and Address PENNANT. Pyers Stevens Hewlett & Perkins 1 Serjeants Inn Fleet Street London EC4 f 1NT United Kingdom	State of Residence The phone No. 44 171 936 2499 Topin Fig. 44 171 936 2498 The phone No. 44 171 936 2498		
3. Further observation of the equation			
$\frac{\mathbf{A}_{i}}{\sum_{i=1}^{N}} \left\{ \begin{array}{cccccccccccccccccccccccccccccccccccc$	The decir step Office (200 percent) X		
The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Dominique DELMAS		

. ATENT COOPERATION TREATY

	From the INTERNATIONAL BUREAU
PCT	To:
NOTIFICATION OF ELECTION (PCT Rule 61.2)	United States Patent and Trademark Office (Box PCT)
	Crystal Plaza 2 Washington, DC 20231 ÉTATS-UNIS D'AMÉRIQUE
Date of mailing (day/month/year) 05 May 1999 (05.05.99)	in its capacity as elected Office
International application No. PCT/GB98/02550	Applicant's or agent's file reference PP/1180
International filing date (day/month/year) 21 August 1998 (21.08.98)	Priority date (day/month/year) 22 August 1997 (22.08.97)
Applicant LICONINS Alicon	
HOPKINS, Alison	
The designated Office is hereby notified of its election made X in the demand filed with the International Preliminary 13 March 1999	Examining Authority on:
in a notice effecting later election filed with the Intern	ational Bureau on:
2. The election X was was not	
made before the expiration of 19 months from the priority (Rule 32.2(b).	date or, where Rule 32 applies, within the time limit under

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland de No.: (41-22) 740.14.35

Authorized officer


Lazar Joseph Panakal

Telephone No. (41-22) 338-83.38

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference		of Transmittal of International Search Report 120) as well as, where applicable, item 5 below.
PP/1180 International application No.	International filing date (day/month/year)	(Earliest) Priority Date (day-month/year)
PCT/GB 98/02550		
Applicant	21/08/1998	22/08/1997
Аррисат		
NYCOMED AMERSHAM PLC et	al.	
	een prepared by this International Searching Auth transmitted to the International Bureau.	nority and is transmitted to the applicant
l —	sts of a total of3sheets. opy of each priorart document cited in this report	
Certain claims were found	unsearchable(see Box I).	
2. Unity of invention is lacking	g(see Box II).	
	contains disclosure of a nucleotide and/or amin oled out on the basis of the sequence listing	o acid sequence listing and the
fi	led with the international application.	
fi	urnished by the applicant separately from the inter	rnational application.
	but not accompanied by a statement to the matter going beyond the disclosure in the	
Т	ranscribed by this Authority	
4. With regard to the title, χ tl	ne text is approved as submitted by the applicant	
tl	ne text has been established by this Authority to re	ead as follows:
5. With regard to the abstract ,	ne text is approved as submitted by the applicant	
	ne text has been established, according to Rule 3	
	Box III. The applicant may, within one month from Search Report, submit comments to this Authority.	
6. The figure of the drawings to be per	ublished with the abstract is:	
	s suggested by the applicant.	None of the figures.
	ecause the applicant failed to suggest a figure.	
	ecause this figure better characterizes the inventi	on.



A. CLASSIFICATION OF SUBJECT MATTER IPC 6 C1201/68

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) IPC 6 C12Q

According to International Patent Classification (IPC) or to both national classification and IPC


Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
X	"stratagene catalogue" January 1997 , STRATAGENE XP002085450 see page 274 - page 277	1		
Y	EP 0 726 310 A (GEN PROBE INC) 14 August 1996 see whole doc, esp. claims 13-27	1-6		
Y	SUGANUMA A. & CUPTA K.C.: "An evaluation of primer length on random-primed DNA synthesis for nucleic acid hybridization: longer is not better" ANALYTICAL BIOCHEMISTRY, vol. 224, - 1995 pages 605-608, XP002085448 cited in the application see the whole document	1-6		
	 -/			

Patent family members are listed in annex.
"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family
Date of mailing of the international search report
08/12/1998
Authorized officer Müller, F


1



INTERIATIONAL SEARCH REPORT




		. 91/GB 98/02550
Category	ation) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication where appropriate of the relevant passages	Relevant to claim No
ategory	Citation of document, with indication, where appropriate, or the relevant passages	nelevani to claim No
Х	DE 195 03 685 A (INVITEK GMBH) 1 August 1996 see whole doc, esp. claims 1, 10,13; page 2,lin15 ff.	1-5
A	DAY I.N.M. ET AL.,: "Dried template DNA, Dride PCR oligonucleotides and mailing in 96-well:LDL receptor gene mutation screening" BIOTECHNIQUES. vol. 18, no. 6, - 1995 pages 981-984, XP002085449 see esp. page 982, 3.column ff.	1-6
A	WO 96 30544 A (WAKEFIELD ANDREW JEREMY) 3 October 1996 see whole doc. esp. claim 14	1-6
A	US 5 407 799 A (STUDIER F WILLIAM) 18 April 1995 see esp. claims (9,10)	1-6



INTEGATIONAL SEARCH REPORT

ational Application No /GB 98/02550

Patent document cited in search repor	t	Publication date		atent family member(s)	Publication date
EP 0726310	A	14-08-1900	US AU CA JP WO US US	5556771 A 4916796 A 2210584 A 10503383 T 9624664 A 5614387 A 5834254 A	17-09-1996 27-08-1996 15-08-1996 31-03-1998 15-08-1996 25-03-1997 10-11-1998
DE 19503685	Α	01-08-1996	NONE		
WO 9630544	Α	03-10-1900	AU CA EP GB	5153196 A 2216807 A 0817864 A 2300259 A	16-10-1996 03-10-1996 14-01-1998 30-10-1996
US 5407799	 А	18-04-1995	NONE		






PCT

REC'D	1	8	NCV	1999
WIPO)	_		PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's	or agent's file reference	See FOR FURTHER ACTION Preli	Notification of Transmittal of International
P/1180		FOR FURTHER ACTION Preli	minary Examination Report (Form PCT/IPEA/416)
nternationa	l application No.	International filing date (day/month/year)	Priority date (day/month/year)
CT/GB9	98/02550	21/08/1998	22/08/1997
nternationa C12Q1/6		PC) or national classification and IPC	
pplicant			
NYCOM	ED AMERSHAM PLO	C et al.	
1. This i	nternational preliminal s transmitted to the ap	ry examination report has been prepared by the plicant according to Article 36.	is International Preliminary Examining Authorit
2. This l	REPORT consists of a	total of 6 sheets, including this cover sheet.	
H	een amended and are	ompanied by ANNEXES, i.e. sheets of the des the basis for this report and/or sheets contain ection 607 of the Administrative Instructions u	ning rectifications made before this Authority
-		A A Loft objects	
lhae	a anneyes consist of a	itotal of sneets.	
Thes	e annexes consist of a	a total of sneets.	
I hes	e annexes consist of a	a total of sneets.	
		ions relating to the following items:	
3. This	report contains indicat	ions relating to the following items:	
3. This	report contains indicat	ions relating to the following items:	
3. This	report contains indicat ☑ Basis of the rep ☐ Priority	ions relating to the following items:	e step and industrial applicability
3. This	report contains indicat ☑ Basis of the rep ☐ Priority	ions relating to the following items: port nent of opinion with regard to novelty, inventiv	e step and industrial applicability
3. This 1 !!	report contains indicat Basis of the report Priority Non-establishm Lack of unity o	ions relating to the following items: port nent of opinion with regard to novelty, inventiv	
3. This 1 11 11 11	report contains indicat Basis of the report Priority Non-establishm Lack of unity o	ions relating to the following items: port ment of opinion with regard to novelty, inventive finvention ement under Article 35(2) with regard to novel explanations suporting such statement	
3. This 1 11 111 1V V	report contains indicat Basis of the report contains indicate Priority Non-establishmath Lack of unity oo Reasoned state citations and ectain documents.	nions relating to the following items: port ment of opinion with regard to novelty, inventive from the following items: ement under Article 35(2) with regard to noveless planations suporting such statement the following such statement in the international application.	
3. This 1 11 11 1V V	report contains indicat Basis of the report contains indicate Priority Non-establishmath Lack of unity oo Reasoned state citations and ectain documents.	ions relating to the following items: port ment of opinion with regard to novelty, inventiv f invention ement under Article 35(2) with regard to novel explanations suporting such statement	
3. This I II IV V VI VIII	report contains indicat Basis of the report contains indicate Priority Non-establishmack of unity of Reasoned state citations and effects Certain document Certain defects Certain observ	port ment of opinion with regard to novelty, inventive from the following items: from the following items: ment of opinion with regard to novelty, inventive from the following items and the following such statement the following such statement in the international application for the international applicatio	
3. This I II IV V VI VIII	report contains indicat Basis of the report contains indicate Priority Non-establishmath Lack of unity oo Reasoned state citations and ectain documents.	port ment of opinion with regard to novelty, inventive from the following items: from the following items: ment of opinion with regard to novelty, inventive from the following items and the following such statement the following such statement in the international application for the international applicatio	ty, inventive step or industrial applicability;
3. This I II IV V VI VIII	report contains indicat Basis of the report contains and the stablishman citations and the contain defects Certain deserves	port ment of opinion with regard to novelty, inventive from the following items: from the following items: ment of opinion with regard to novelty, inventive from the following items and the following such statement the following such statement in the international application for the international applicatio	ty, inventive step or industrial applicability;
3. This I II III IV V VI VII VIII Date of su 13/03/1	report contains indicat Basis of the report contains and the stablishment of the following server is the server of the indication of the demand server is the server of the indication of the demand server is the server of the	port ment of opinion with regard to novelty, inventive from the following items: from the following items: from the following items: from the from the following items: from the from the from the following items: from the from th	ty, inventive step or industrial applicability; letion of this report 1 5. 11. 95
3. This I II IV V VI VII VIII Date of su 13/03/1	report contains indicat Basis of the report contains indicat Priority Non-establishmack of unity of Reasoned state citations and effects Certain documtocertain contain cont	ions relating to the following items: port ment of opinion with regard to novelty, inventive from the invention of a superior	ty, inventive step or industrial applicability; letion of this report 1 5. 11. 95
3. This I II III IV V VI VII VIII Date of su 13/03/1	report contains indicat Basis of the report contains and the stablishment of the following server is the server of the indication of the demand server is the server of the indication of the demand server is the server of the	ions relating to the following items: port ment of opinion with regard to novelty, inventive finvention ement under Article 35(2) with regard to novel explanations suporting such statement enents cited in the international application exations on the international application. Date of comparts of the comparts of t	ty, inventive step or industrial applicability; letion of this report 1.5. 11. 93.



INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/GB98/02550

l.	Basis	of the	report
----	--------------	--------	--------

Claims, No.:

1-6

response to an invitation	Irawn on the basis of (substitute sheets which have been furnished to the receiving Office in on under Article 14 are referred to in this report as "originally filed" and are not annexed to lo not contain amendments.):
Description, pages:	
1-11	as originally filed

2.	The amendments have resulted in the cancellation o	f:
----	----------------------------------------------------	----


as originally filed

the description,	pages:
the claims,	Nos.:
the drawings,	sheets

- 3.
 This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):
- 4. Additional observations, if necessary:
- V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)		Claims Claims	
Inventive step (IS)	,	Claims Claims	
Industrial applicability (IA)		Claims Claims	



INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/GB98/02550


2. Citations and explanations

see separate sheet

VII. Certain defects in the international application

The following defects in the form or contents of the international application have been noted:

see separate sheet



Section V

Reference is made to the following documents:

D1: EP-A-0 531 027

D2: EP-A-0 726 310

D3: SUGANUMA A. & CUPTA K.C.: 'An evaluation of primer length on random-primed DNA synthesis for nucleic acid hybridization: longer is not better' ANALYTICAL BIOCHEMISTRY, vol. 224, - 1995 pages 605-608.

D4: DE-A-195 03 685


The documents D1 was not cited in the international search report (cf. PCT Guidelines, Chap. VI-7.24).

1. The document D1 shows the use of a labelling composition comprising a random mixture of oligonucleotide primers, preferably 6 to 9 nucleotides in length (cf. p.3, 1.25-26 and claim 3). A dried labelling composition comprising a mixture of random 9-mer primers is disclosed p.4, 1.11-27. A method of making labelled probes for a nucleic acid template by using the said 6 to 9-mer oligonucleotides is also disclosed (cf. p.3, "description of the invention").

The applicant argue that a dried mixture of oligonucleotides which are 6 to 8 mers is not disclosed in D1, however this argument cannot be accepted for the following reasons.

In D1, the description and example 1 are considered to represent connected information. Thus, when carrying out the method described in D1 (i.e. when producing the set of oligunucleotides which are 6 to 9 mers), the skilled person would automatically arrive at a dried composition falling within the scope of claims 1 and 3 of the present application and a method being the subject-matter of claim 5.


Therefore, the subject-matter of claims 1, 3 and 5 does not meet the requirements of Art. 33(2) PCT.



- 2. The dependent claims 2, 4 and 6 do not contain any features which, in combination with the features of any claim to which they refer, meet the requirements of the PCT in respect of inventive step (Art. 33(3) PCT), the reasons being as follows:
 - 2.1 D1 discloses a kit for making labelled probes comprising the random mixture of oligonucleotides and a polymerase enzyme, a supply of nucleotides for chain extension and a buffer (p.3, l.51-55).
 Adding a labelled nucleotide is merely one of several straightforward possibilities from which the skilled person would select, in accordance with circumstances, without the exercise of inventive skill (cf. D1, p.3, l.32 and p.4, l.37). Adding a dye to such a composition is common in the art (cf. the present application, p.2, l.16). The use of a stabiliser (e.g. trehalose) is also common for enzyme-containing dried compositions (cf. D2, p.5, l.33-39). It would therefore be obvious to the person skilled in the art, to combine these features with corresponding effect, thereby arriving at a composition according to claim 2.
 - 2.2 The feature of dependent claim 4 has already been employed for the same purpose for a similar composition (cf. the present application, p.2, l.15, or D2, p.5, l.55 and example 6 on p.15).
 - 2.3 Making labelled probes using a random mixture of oligonucleotides at a final concentration falling within the range of 2-10 OD/ml is known from the prior art (e.g. in D3 which is also dealing with random mixtures of oligonucleotides and the use thereof, p.606, c.1, l.1-3, where 12.5 μ l of reaction mixture contain 8.5 μ l of previously made primer-template mixture containing 2.5 μ g of random oligonucleotides, that means a final concentration of 200 μ g/ml which should give an OD/ml of about 6.0, since 1.0 A₂₆₀ unit ss DNA= 33 μ g/ml).

Consequently, the subject-matter of claim 6 also lacks an inventive step.


3. The claimed subject-matter is considered to be novel over D4 (Art. 33(2) PCT) since a random mixture of oligonucleotides which are 6-mers to 8-mers is not disclosed therein.



INTERNATIONAL PRELIMINARY International application No. PCT/GB98/02550 EXAMINATION REPORT - SEPARATE SHEET

Section VII

Contrary to the requirements of Rule 5.1(a)(ii) PCT, the relevant background art disclosed in the documents D1 is not mentioned in the description, nor is this document identified therein.



WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ :	A1	(11) International Publication Number: WO 99/10531
C12Q 1/68		(43) International Publication Date: 4 March 1999 (04.03.99)
(21) International Application Number: PCT/GB (22) International Filing Date: 21 August 1998 (CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
(30) Priority Data: 9717972.5 22 August 1997 (22.08.97)	C	Published With international search report.
(71) Applicant (for all designated States except US): NY AMERSHAM PLC [GB/GB]; Amersham Place, Li font, Buckinghamshire HP7 9NA (GB).		
(72) Inventor; and (75) Inventor/Applicant (for US only): HOPKINS, [GB/GB]; 39 Park Terrace, Tondu, Bridgend, Mid gan CF32 9HE (GB).		
(74) Agents: PENNANT, Pyers et al.; Stevens Hewlett & 1 Serjeants' Inn, Fleet Street, London EC4Y 1LL		s,
(54) Title: LABELLING COMPOSITION AND METHO	D	

(57) Abstract


A labelling composition comprises a random mixture of oligonucleotides which are 6-mers to 8-mers, said composition present in a dry state. A method of making labelled probes for a nucleic acid template comprises incubating the template under chain extension conditions with the labelling composition. The use of 6-mers to 8-mers reduces self-annealing, which is a problem with 9-mers in a dried



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

					-		
AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
ΛZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	ТJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Сапада	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	zw	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		



WO 99/10531 PCT/GB98/02550

- 1 -

LABELLING COMPOSITION AND METHOD

This invention concerns compositions comprising random mixtures of oligonucleotides and their use for labelling nucleic acids by a random prime method.

5

10

15

20

25


30

Feinberg and Vogelstein (1, 2) introduced the use of random sequence hexanucleotides to prime DNA synthesis on denatured template DNA at numerous sites along its length. The primer-template complex is a substrate for the "Klenow" fragment of DNA polymerase I. By replacing a non-radioactive nucleotide with the radiolabelled equivalent in the reaction mixture, newly synthesised DNA is made radioactive.

Very small amounts of input DNA can be labelled, enabling very high specific activity probes to be produced with relatively small quantities of added nucleotides. These radioactive labelled fragments can then be used as sensitive hybridisation probes for a wide range of filter based applications (3-6).

There are several labelling kits that are commercially available for the labelling of DNA by the random prime method. These include the Multiprime, Megaprime, Rediprime and Fluorescein Gene Images kits available from Amersham International plc. Ready-To-Go kits are available from Pharmacia and High Prime kits are available from Boehringer.

The Multiprime kit was introduced in the 1980s. It provides different tubes containing the different solutions that enable the user to make up labelling mixtures. One such tube contains a random mixture of 6-mer oligonucleotides, another the polymerase enzyme, and another the supply of nucleotides in the reaction buffer. All these separate solutions are stored frozen at -20°C. The purchaser thaws the different solutions, and adds precise quantities of each to the sample of denatured DNA that is



WO 99/10531 PCT/GB98/02550

- 2 -

to be labelled, including a labelled nucleotide. This reaction is then usually incubated at 37°C at which temperature, oligonucleotide annealing and chain extension can occur. However, the reaction may also be incubated at lower temperatures such as an ambient room temperature of about 20°C.

The Megaprime kit was introduced commercially in the early 1990s. It is similar to the Multiprime kit, except that 9-mer oligonucleotides are used in place of 6-mers. The Megaprime kit has an advantage over the Multiprime kit, in that 9-mer oligonucleotides anneal more strongly (than do 6-mers) to a DNA target and form a hybrid having a higher melting temperature. Thus 9-mers achieve better and more rapid priming of a target then do 6-mers.

10

15

20


25

30

The Rediprime kit was introduced commercially in 1994. It comprises a mixture of 9-mer oligonucleotides with a polymerase enzyme and a supply of nucleotides. The mixture is supplied in a freeze-dried state. The freeze-dried mixture also contains a dye for easy visualisation. Dried kits for performing nucleic acid manipulation experiments were described by Ortlepp and McKay in EP 298 669 entitled "Performing nucleic acid reactions". The user reconstitutes the mixture by adding liquid containing the DNA template that is to be labelled, and then liquid containing the labelled nucleotide.

The Ready-To-Go kit was introduced during the 1990s. It is based on a random prime solution containing a random mixture of 9-mer or longer oligonucleotides, which solution is dried by a technique described in EP 383 569. A dye is not present. Like the Rediprime kit, the Ready-To-Go kit can be stored at +4°C or at ambient temperature. Promotional literature emphasises the speed of labelling, which results from the use of 9-mer oligonucleotides.

The High Prime kit is a wet kit containing a random mixture of oligonucleotides. The kit literature does not indicate what length of random oligonucleotides are used, but in the related document EP 649 909 A2, the



WO 99/10531 PCT/GB98/02550

- 3 -

use of 6-mer, 9-mer, 12-mer and 15-mer is disclosed. No preferred length of random oligonucleotide is given. The solution is stablised by the use of glycerol and can be stored at between about -20°C and +4°C.

5

10

15

20


25

30

It can be seen that there has been a trend in commercial kits towards the use of longer oligonucleotides, particularly 9-mers or even longer. Going against this trend, it has been determined by Suganuma, A and Gupta, K C (7) that the use of long random primers, especially 9-mers or longer, reduces the priming efficiency of the random primer reaction. These authors worked on solutions which were used without being dried at any stage. The conclusions of these authors conflict with the findings of the present inventors; which findings are to the effect that, when experiments are done with solutions which are not dried, 9-mers provide more rapid and efficient labelling than do 6-mers, and do not give rise to any problem resulting from self-annealing or self-priming. To the best of applicants' knowledge, the conclusions reported by the authors of (7) have not caused the suppliers of random prime kits to use shorter oligonucleotides.

The present invention is based on the discovery that self-annealing occurs when random 9-mers are used in dried predispensed labelling kits, and that this limits their stability and shelf life. The self-annealing occurs during dispensing and storage when the random 9-mers anneal together to form primer-dimers or primer concatemers. These primer complexes become labelled during the normal labelling reaction, which concomitantly reduces the amount of label that is incorporated into copies of the template that are being synthesised during the reaction. Shorter oligonucleotides are not subject to this problem. The problem is specific to 9-mers (and longer oligonucleotides) used in dried kits.

The invention provides a labelling composition comprising a random mixture of oligonucleotides which are 6-mers to 8-mers, said composition present in a dry state. Preferably the composition also contains at least one of: a polymerase enzyme; a supply of nucleotides for



WO 99/10531 PCT/GB98/02550

- 4 -

chain extension; a labelled nucleotide; a dye; a stabiliser; and a buffer.

As the experimental data below shows, 5-mer oligonucleotides are too short to be useful in dried kits. As the length of the oligonucleotides increases from 6-mers to 9-mers, there is a concomitant increase in the aforementioned self-priming problem. On the other hand, longer oligonucleotides anneal more rapidly and strongly to templates than do shorter ones. Taking into account both these factors, applicants believe that 6-mer oligonucleotides are more preferable than 7-mers which in turn are more preferable than 8-mers.

The random mixture of oligonucleotides is present in a dry state. Various drying techniques are possible, including that described in EP 383 569, and also freeze-drying or lyophilisation which is preferred.

10

15

20


25

30

It is possible to use any DNA polymerase enzyme in the labelling reaction, for example Klenow, exonuclease free klenow, DNA polymerase I, T7 DNA polymerase, SequenaseTM, ThermosequenaseTM, so long as the reaction buffer conditions are suitable for the specific enzyme being used.

All four of the nucleotides are preferably present in the composition, whether labelled or unlabelled, and the relative molar concentrations may be adjusted to improve the efficiency of labelling. Also when a labelled nucleotide is present, the equivalent unlabelled nucleotide may also be present to improve the efficiency of labelling, or to control the specific activity of the DNA that is being produced from the labelling reaction.

These compositions enable a DNA template to be used to produce copies which are labelled radioactively, for example, by using either phosphate labelled with P-32 or S-35, or by using H-3 or C-14 base labelled nucleotides. Alternatively non-radioactive labels may be used, for example, fluorescein, biotin, digoxigenin, rhodamine and cyanine dyes, may be incorporated when, for example, covalently linked to the base moiety of the nucleotide.



10

15


Any stabiliser may be present to protect the activity of the enzyme, for example, trehalose, sucrose, BSA, gelatin. A dye may also be present to allow the dried pellet to be visualised, before use, and to assist in determining that mixing is thorough.

The invention also includes a method of making labelled probes for a nucleic acid template, which method comprises incubating the nucleic acid template under chain extension conditions with the labelling composition as herein described. Preferably the template is DNA. The inventor has found that random 6-mers can give fast labelling kinetics (10 minutes labelling time) by being present at high concentration in the reaction mixture. A preferred concentration is 2-10 O.D./ml in the final reaction with about 5 O.D./ml being most preferable. A probe labelled in this manner is suitable for use in a Southern hybridisation.

All the results shown in the examples show labelling with dCTP-³²P, but this is only as a means to show, and quantitate the amount of self-priming that occurred in each reaction. The reactions are able to label DNA with other labels, both radioactive and non-radioactive, as indicated elsewhere in this specification.

20 References

- 1. Feinberg, A P and Vogelstein, B, Anal. Biochem., 132: 6-13 (1983).
- 2. Feinberg, A P and Vogelstein, B, Addendum Anal. Biochem., 137: 266-267 (1984).
- 25 3. Southern, E M, J. Mol. Biol., 98: 503-517 (1975).
 - 4. Thomas, P S, Proc. Nat. Acad. Sci., USA, 77: 5201-5205 (1980).
 - 5. Meinkoth, J and Wahl, G, Anal. Biochem, 138: 267-284 (1984).
- Grunstein, M and Hogness, D S, Proc. Natl. Acad. Sci, USA,
 72: 3961-3965 (1975).



7. Sugunuma, A and Gupta, K C, Analytical Biochemistry, 224: 605-608 (1995).

Example 1. Manufacture of lyophilised reactions with different random primer lengths:

All primers were diluted to 50 O.D./ml in water. The number of enzyme units was the same in each reaction (7 units).


The amount of each component solution is as follows for a 6 ml scale.

10

5

	5 mer reaction mix	6 mer reaction mix	7 mer reaction mix	8 mer reaction mix	9 mer reaction mix
Nucleotide buffer	1.998 ml	1.998 ml	1.998 ml	1.998 ml	1.998 ml
Exo-free Klenow (12 μl) 100 units/μl	1200 units	1200 units	1200 units	1200 units	1200 units
Dilution Buffer	28 μΙ	اμ 28	28 μΙ	28 μί	28 μΙ
5 mer primer	1.0 ml				
6 mer primer		1.0 ml			
7 mer primer			1.0 ml		
8 mer primer				1.0 ml	
9 mer primer					1.0 ml
20% Trehalose	1.5 ml	1.5 ml	1.5 ml	1.5 ml	1.5 ml
0.2 mg/ml Xylene Cyanol	0.198 ml	0.198 ml	0.198 ml	0.198 ml	0.198 ml
PF Water	1.264 ml	1.264 ml	1.264 ml	1.264 ml	1.264 ml
Total Volume	6 ml	6 ml	6 ml	6 ml	6 ml

Each reaction mix was dispensed into tubes in 35 μ l aliquots, and were freeze dried.



15

20

25

Methods:

- 1. Nucleotide buffer: Labelling buffer from Nick Translation kit (N5000/N5500 Amersham International plc).
- 2. Dilution buffer: Storage buffer for enzyme dilution.
- 5 3. Labelling Method: Tubes of DNA for labelling were made up as follows:

 $5~\mu l~\lambda$ HindIII DNA at $5~ng/\mu l$ in TE buffer. 40 μl water.

Placed all tubes in a boiling water bath (95 to 100°C) for 5 minutes.

placed all tubes on ice for 5 minutes, centrifuged briefly,
then added the denatured DNA solutions to the respective
dried reaction tube samples

added 5 μ l RedivueTM dCTP (α^{32} P) (Product Code AA0005: Amersham International plc) (50 μ l total reaction volume).


Incubated all reactions for 10 minutes at 37°C.

Spotted 2 μl samples out onto PEI-cellulose tlc plates,

Ran plates in 1.25 M KH₂PO₄ pH 3.4.

Analysed plates on plate scanner, to measure the %incorporation, %self-priming and %dCTP present at the end of each reaction.

The %self-priming is defined as the % of the total radioactive counts that are situated between the incorporated counts and the counts due to the unincorporated dCTP-³²P.



15


λ Hindlll DNA Labelling with dCTP-32P (Week 1 Test)

		Tube-1			Tube-2		
Tube	Primer Type	% Incorp	% Self- Prime	% dCTP	% Incorp	% Self- Prime	% dCTP
1, 2	5 mers	62.7	7.9	23.0	54.8	7.7	30.9
3, 4	6 mers	79.9	11.2	2.7	82.1	10.8	2.2
5, 6	7 mers	73.5	17.5	2.8	74.3	15.1	3.7
7, 8	8 mers	68.3	19.1	3.2	65.6	20.4	3.6
9, 10	9 mers	64.9	23.7	3.1	61.5	27.2	3.1

The column headed "% Incorp" shows the percentage of dCTP-³²P incorporated as a chain extension product of a primer-λHind III DNA hybrid. The column headed "% Self-Prime" shows the percentage of dCTP-³²P incorporated in a complex involving only primers. The column headed "% dCTP" shows the percent of unincorporated dCTP-³²P. The % dCTP figures were unacceptably high when 5-mer oligonucleotides were used, but were acceptable for 6-mers to 9-mers. Within this range, the % Incorp figures decrease as the oligonucleotide length increases from 6 to 9.

<u>Example 2</u>. Long term stability comparison of dried reactions, nonamers compared with hexamers, 3.5 units of Exo-free Klenow per reaction:

The samples were made up as shown in Example 1, but 6 μ l of Exo-free Klenow was used.



DNA Labelling with dCTP-³²P, results are the averages of the three reactions

	Nonamers			Hexamers		
Week	% Incorp	% Self- Prime	% dCTP	% Incorp	% Self- Prime	% dCTP
3	61.9	17.5	6.2	69.6	9.7	6.3
6	71.4	18.0	4.3	80.8	8.4	4.7
10	65.8	20.2	6.4	75.0	11.9	6.9
16	66.5	16.5	8.0	73.4	11.1	6.5
21	78.3	10.8	3.0	84.3	5.8	2.4
25	42.7	11.6	40.4	55.1	5.4	35.1


As these figures show, the % incorporation of dCTP-³²P when using 9-mers was initially lower than when using 6-mers and remained lower on storage of the compositions for up to 25 weeks.

Example 3:

5

10

Using dried reactions as shown in Example 1, the primer was replaced with water for the reaction drying, and was added later as a separate solution, when the reactions were being used. All reactions were incubated for 10 minutes, and then sampled to measure the % incorporation.



WO 99/10531 PCT/GB98/02550

- 10 -

Primer Concentration	% Incorporation	% Incorporation
in reaction	(hexamer primers)	(nonamer primers)
O.D./ml	Average of two reactions	one reaction
6.0	78.3	
5.0	83.2	81.0
4.0	67.7	65.6
2.0	51.5	67.0
1.0	45.1	60.2

It can be seen from these results that the same primer concentration (O.D./ml) is required to achieve the same reaction kinetics, i.e. the same % incorporation in 10 minutes with different random primer lengths. This shows that the molar concentration needs to increase as the primer length is reduced.

Although the above results were obtained using wet reagents, the conclusion would apply also when dry primers are used.

Example 4:


10

15

20

Densitometer results of Southern hybridisations


25ng labelling reactions were carried out using the Megaprime Labelling Kit RPN 1606 (Amersham International plc) or using labelled probes from dried nonamer or hexamer labelling reactions made as described above in other examples. Southern blots were hybridised for 2 hours at 65°C with the labelled probe under standard conditions and then washed in 2 x SSC, 0.1% SDS, 20 minutes at room temperature, followed by two washes in 0.5 x SSC, 0.1% SDS, for 5 minutes 65°C. The dried blots were detected on X-ray film with 2 intensifying screens and place into a -70°C freezer, for 16 hours. After the film was developed using a film processor it was scanned using a densitometer, then the results were analysed using ImageQuant software.



Kit	Time of test after manufacture	Target	%band intensity of Southern hybridisation cf Megaprime control
9mers	1 week	0.25pg	42.23
9mers	1 week	0.5pg	40.12
9mers	1 week	1.0pg	38.93
6mers	1 week	0.25pg	97.09
6mers	1 week	0.5pg	95.02
6mers	1 week	1.0pg	94.33
6mers	37 weeks	0.25pg	74.58
6mers	37 weeks	0.5pg	80.91
6mers	37 weeks	1.0pg	81.17


Conclusions:

The hexamers used in a dried labelling reaction generate
labelled probes which gave a much stronger band intensity than when
nonamers are used, not only when tested initially after 1 week, but even
after an extended period of storage (37 weeks at room temperature).



CLAIMS

- 5 1. A labelling composition comprising a random mixture of oligonucleotides which are 6-mers to 8-mers, said composition present in a dry state.
 - 2. A labelling composition as claimed in claim 1, wherein the composition also contains at least one of: a polymerase enzyme; a supply of nucleotides for chain extension; a labelled nucleotide; a dye; a stabiliser; and a buffer.
 - 3. A labelling composition as claimed in claim 1 or claim 2, wherein the random mixture is of 6-mer oligonucleotides.
 - 4. A labelling composition as claimed in any one of claims 1 to
- 15 3, wherein the composition is present in a freeze-dried state.
 - 5. A method of making labelled probes for a nucleic acid template, which method comprises incubating the nucleic acid template under chain extension conditions with the labelling composition of any one of claims 1 to 4.
- 20 6. A method as claimed in claim 5, wherein the random mixture of oligonucleotides is present at a concentration of 2-10 O.D./ml.



inal Application No PCT/GB 98/02550

A. CL	ASSIFI		OF SU	MA	TTER
IPC	Ó	0120	01/68		

According to international Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED


Minimum documentation searched (classification system followed by classification symbols) IPC 6 C12Q


Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

Category [©]	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	"stratagene catalogue" January 1997 , STRATAGENE XP002085450 see page 274 - page 277	1
Y	EP 0 726 310 A (GEN PROBE INC) 14 August 1996 see whole doc, esp. claims 13-27	1-6
Y	SUGANUMA A. & CUPTA K.C.: "An evaluation of primer length on random-primed DNA synthesis for nucleic acid hybridization: longer is not better" ANALYTICAL BIOCHEMISTRY, vol. 224, - 1995 pages 605-608, XP002085448 cited in the application see the whole document	1-6
	-/	


X Further documents are listed in the continuation of box C	Patent family members are listed in annex.				
* Special categories of cited documents	"T" fater document published after the international filing date				
"A" document defining the general state of the lart which is not considered to be of particular relevance."	or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention				
"E" earlier document but published on or after the international filing date	"X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance, the claimed invention				
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another state of the st					
citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means	cannot be considered to involve an inventive step when the document is combined with one or more other such docu- ments, such combination being obvious to a person skilled				
"P" document published prior to the international filling date but later than the priority date claimed	in the art &" document member of the same patent family				
Date of the actual completion of the international search	Date of mailing of the international search report				
24 November 1998	08/12/1998				
Name and mailing address of the ISA	Authorized officer				
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo ni, Fax: (+31-70) 340-3016	Müller, F				





Inte onal Application No
PCT/GB 98/02550

C.(Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	PC1/GB 98/02550
ategory	Citation of document with indication where appropriate of the relevant passages	Relevant to claim No
X	DE 195 03 685 A (INVITEK GMBH) 1 August 1996 see whole doc, esp. claims 1, 10,13; page 2,lin15 ff.	1-5
A	DAY I.N.M. ET AL: "Dried template DNA, Dride PCR oligonucleotides and mailing in 96-well:LDL receptor gene mutation screening" BIOTECHNIQUES, vol. 18, no. 6, - 1995 pages 981-984, XP002085449 see esp. page 982, 3.column ff.	1-6
1	WO 96 30544 A (WAKEFIELD ANDREW JEREMY) 3 October 1996 see whole doc. esp. claim 14	1-6
<i>,</i>	US 5 407 799 A (STUDIER F WILLIAM) 18 April 1995 see esp. claims (9,10)	1-6



Information on patent family members

line

onal Application No

PCT/GB 98/02550

Patent document oited in search report		Publication date		atent family nember(s)	Publication date	
EP	P 0726310 A 14-08-1900		14-08-1900	US	5556771 A	17-09-1996
				ΑU	4916796 A	27-08-1996
				CA	2210584 A	15-08-1996
				JP	10 5 03383 T	31-03-1998
				WO	9624664 A	15-08-1996
				US	5614387 A	25-03-1997
				US	5834254 A	10-11-1998
DE	19503685	Α	01-08-1996	NONE		
WO	9630544	- A	03-10-1900	AU	5153196 A	16-10-1996
				CA	2216807 A	03-10-1996
				EP	0817864 A	14-01-1998
				GB	2300259 A	30-10-1996
US	5407799	- -	18-04-1995	NONE		

